Guanine-utilizing enzymes and nucleic acids

Guanine-utilizing enzymes and nucleic acids represent a broad functional category of therapeutic targets involved in the synthesis, salvage, and utilization of guanine nucleotides. This group includes critical enzymes such as hypoxanthine-guanine phosphoribosyltransferase (HGPRT), which facilitates the purine salvage pathway, and inosine monophosphate dehydrogenase (IMPDH), a key regulator of de novo guanosine triphosphate (GTP) biosynthesis (UniProt: P00492, P20839). Furthermore, it encompasses DNA and RNA molecules into which guanine analogs can be incorporated, disrupting genetic stability and protein synthesis (PubChem: CID 2723601). Drugs targeting these entities, such as thiopurines and guanosine-based antivirals, are widely used in the treatment of leukemias, inflammatory conditions, and viral infections (PubMed: PMID 15588231). By mimicking natural guanine, these therapeutic agents interfere with nucleic acid synthesis or inhibit specific metabolic steps, ultimately leading to cell death or viral suppression (StatPearls: Acyclovir). Clinical management often requires monitoring of metabolic enzymes like TPMT to mitigate risks of severe myelosuppression (FDA: Thiopurine Methyltransferase).

Other names

Guanine metabolism enzymesGuanine-related targetsPurine-utilizing enzymes and nucleic acids

Inhibition of de novo purine synthesis, inhibition of the purine salvage pathway, and incorporation into DNA or RNA as fraudulent nucleotides leading to chain termination or mutagenesis (PubMed: PMID 15588231, StatPearls: Acyclovir).